Business Description
Can Fite Biofarma Ltd
ISIN : US13471N1028
Share Class Description:
CANF: ADRCompare
Compare
Traded in other countries / regions
CANF.IsraelCANF.USACF5.Germany IPO Date
2012-09-10Description
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 82.61 | |||||
| Equity-to-Asset | 0.42 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -38.59 | |||||
| WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -37 | |||||
| 3-Year EBITDA Growth Rate | 45.5 | |||||
| 3-Year EPS without NRI Growth Rate | 37 | |||||
| 3-Year FCF Growth Rate | 41.7 | |||||
| 3-Year Book Growth Rate | -28.8 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 63.66 | |||||
| 9-Day RSI | 63.58 | |||||
| 14-Day RSI | 60.39 | |||||
| 3-1 Month Momentum % | -32.73 | |||||
| 6-1 Month Momentum % | -33.33 | |||||
| 12-1 Month Momentum % | -30.84 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.93 | |||||
| Quick Ratio | 2.93 | |||||
| Cash Ratio | 2.38 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -43.1 | |||||
| Shareholder Yield % | 0.13 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -1103.44 | |||||
| Net Margin % | -1027.95 | |||||
| FCF Margin % | -1136.2 | |||||
| ROE % | -146.6 | |||||
| ROA % | -84.56 | |||||
| ROIC % | -807.14 | |||||
| 3-Year ROIIC % | 717.89 | |||||
| ROC (Joel Greenblatt) % | -8130.94 | |||||
| ROCE % | -118.5 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 5.59 | |||||
| PS Ratio | 6.67 | |||||
| PB Ratio | 4 | |||||
| Price-to-Tangible-Book | 2 | |||||
| EV-to-EBIT | -0.68 | |||||
| EV-to-Forward-EBIT | 0.41 | |||||
| EV-to-EBITDA | -0.68 | |||||
| EV-to-Revenue | 7.52 | |||||
| EV-to-Forward-Revenue | 0.56 | |||||
| EV-to-FCF | -0.65 | |||||
| Price-to-GF-Value | 0.47 | |||||
| Price-to-Net-Current-Asset-Value | 2 | |||||
| Earnings Yield (Greenblatt) % | -147.06 | |||||
| FCF Yield % | -82 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with AMEX:CANF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Can Fite Biofarma Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.743 | ||
| EPS (TTM) ($) | -3 | ||
| Beta | 1.09 | ||
| 3-Year Sharpe Ratio | -0.84 | ||
| 3-Year Sortino Ratio | -1.03 | ||
| Volatility % | 58.06 | ||
| 14-Day RSI | 60.39 | ||
| 14-Day ATR ($) | 0.118458 | ||
| 20-Day SMA ($) | 1.56851 | ||
| 12-1 Month Momentum % | -30.84 | ||
| 52-Week Range ($) | 1.29 - 4.69 | ||
| Shares Outstanding (Mil) | 6.1 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Can Fite Biofarma Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Can Fite Biofarma Ltd Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Can Fite Biofarma Ltd Frequently Asked Questions
What is Can Fite Biofarma Ltd(CANF)'s stock price today?
The current price of CANF is $1.76. The 52 week high of CANF is $4.69 and 52 week low is $1.29.
When is next earnings date of Can Fite Biofarma Ltd(CANF)?
The next earnings date of Can Fite Biofarma Ltd(CANF) is 2025-03-28 Est..
Does Can Fite Biofarma Ltd(CANF) pay dividends? If so, how much?
Can Fite Biofarma Ltd(CANF) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers